



73.9%

PHYSICIAN OFFICE VISITS INVOLVING DRUG THERAPY
in United States¹



2.9 BILLION DRUGS ORDERED¹

OR PROVIDED IN UNITED STATES



47 PERCENT GROWTH



WILL ORIGINATE FROM
NORTH AMERICA²



GLOBAL TDM MARKET EXPECTED TO INCREASE BY

998 MILLION²



THERAPEUTIC DRUG MONITORING

An effective therapeutic drug monitoring program requires a broad menu of high-quality assays to support testing laboratories' goals.

SYVA® Enzyme Multiplied Immunoassay Technique (EMIT®) therapeutic drug monitoring panel offers a comprehensive menu of reliable assays for testing on the AU480, AU680, AU5800 and DxC 700 AU analyzers. Coupled with Beckman Coulter instruments, SYVA EMIT assays can provide accurate, efficient analysis of anticonvulsants, antiarrhythmics, aminoglycoside antibiotics and antiasthmatics.

LEARN ABOUT
BECKMAN
COULTER'S
THERAPEUTIC DRUG
MONITORING MENU





THE NEED FOR RELIABLE TESTING

Since the 1970s, the therapeutic drug monitoring (TDM) assay has been used to help physicians monitor and maintain drug levels within a specific therapeutic range.³ The therapeutic range is the concentration range in which a drug exerts its clinical effect with minimal adverse effects for most patients.⁴

For some drugs, maintaining this steady state can be difficult, because each person absorbs, metabolizes, utilizes and eliminates drugs differently. Additionally, therapeutic drug-monitoring rates may change over time—even on a daily basis—depending on disease states and interactions with other medications.

TDM assays can also assist in determining the patient's noncompliance (e.g., when the person does not take a prescribed medication regularly) and the effect of drug interactions, which may cause higher- or lower-than-expected drug concentrations at a given dosage.⁵ In short, drug monitoring helps personalize a dose to fit the specific needs of the patient.

PRODUCT BENEFITS

Beckman Coulter offers a comprehensive panel of TDM assays, allowing greater consolidation of testing on one system. Beckman Coulter's SYVA EMIT TDM assays also deliver high-quality performance, giving technologists confidence in reported results.

In addition, SYVA EMIT TDM combines the specificity and sensitivity of immunoassay with the convenient speed and reproducibility of enzyme measurements. These high-quality assays help to improve patient care, while meeting the routine TDM assays combine requirements of the laboratory. Furthermore, SYVA EMIT helps optimize laboratory operations for clinical and operational efficiency.

METHODOLOGY

SYVA EMIT TDM chemistry utilizes a homogenous enzyme immunoassay method. The assay is based on competition between the drug in the specimen and the drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for antibody binding sites. Since enzyme activity decreases upon binding to the antibody, the drug concentration is measured in terms of enzyme activity.

Active enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH—the reduced form of NAD—resulting in an absorbance change that is measured spectrophotometrically at 340 nm. Endogenous G6PDH does not interfere, because the coenzyme NAD functions only with the bacterial (i.e., *Leuconostoc mesenteroides*) enzyme employed in the assay.

Semiquantitative results are calculated through the use of multiple calibrator levels to provide an approximate cumulative concentration of the drugs and metabolites detected by the reagent. The results obtained during this screen provide a reliable estimate of the drug concentration, which can be used to prepare an appropriate dilution for gas chromatography and mass spectrometry (GC/MS) confirmatory testing. Semiquantitative drug screening reagents can be a valuable tool to evaluate drug treatment plan compliance and drug overdose medical emergencies.

SYVA EMIT Therapeutic Drug Monitoring assays feature:



Ready-to-use, all-liquid reagents, controls and calibrators with convenient storage at 2-8° C (36-46° F)



Prefilled, ready-to-use AU barcoded reagent cartridges



Enhanced formulation—eliminates interferences from hemolysis, lipemia and bilirubin



Common sample types—serum and plasma

TDM MENU OFFERING		
Acetaminophen	Gentamicin	Procainamide
Amikacin*	Lidocaine*	Quinidine
Caffeine*	Methotrexate*	Salicylic Acid
Carbamazepine	N-Acetylprocainamide	Theophylline
Digoxin	Phenobarbital	Tobramycin
Disopyramide*	Phenytoin	Valproic Acid
Ethosuximide*	Primidone*	Vancomycin

*Siemens SYVA® EMIT® off-the-shelf kits are NOT packaged in AU bottles.

Our therapeutic drug monitoring test menu is available on these Automated Clinical Chemistry Analyzers.

Learn more at www.beckmancoulter.com



References

1. Centers for Disease Control and Prevention <https://www.cdc.gov/nchs/fastats/drug-use-therapeutic.htm>
2. Therapeutic Drug Monitoring Market by Product, End-user, Drug Class, and Geography - Forecast and Analysis 2020-2024. <https://www.technavio.com/report/therapeutic-drug-monitoring-market-industry-analysis>
3. Touw, DJ et al. "Cost-effectiveness of Therapeutic Drug Monitoring: A Systematic Review." *Ther Drug Monit*, vol. 27. 2005, pp. 10-7.
4. Birkett, DJ et al. "Therapeutic Drug Monitoring." *Aust Prescr*, vol. 20. 1997, pp. 9-11.
5. Tange, SM et al. "Therapeutic Drug Monitoring in Pediatrics: A Need for Improvement." *J Clin Pharmacol*, vol. 34. 1994, pp. 200-14.

Siemens is a trademark of Siemens Healthcare Diagnostics, Inc. used under license agreement.

© 2021 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

For Beckman Coulter's worldwide office locations and phone numbers, please visit www.beckmancoulter.com/contact

BR-326450 | 2021-9350

